Company Profiles

driven by the PitchBook Platform

AB2 Bio

AB2 Bio
2010 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
$20.9M LATEST DEAL AMOUNT
$52.1M TOTAL AMOUNT RAISED
1 INVESTORS
Description

Drug developers for inflammation-based diseases. The company develops treatments and medicines for inflammatory and autoimmune diseases.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Primary Office
EPFL Innovation Park
Building B, 4th Floor
1015 Lausanne
Switzerland

+41 (0)21 693 8280
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AB2 Bio’s full profile, request a free trial.

AB2 Bio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 14-Jan-2016 $20.9M $52.1M Completed Generating Revenue
2. Accelerator/Incubator 000.00 Completed Startup
1. Early Stage VC $31.2M $31.2M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

AB2 Bio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
EPFL Innovation Park Accelerator/Incubator 000 0000 000000 0

You’re viewing 1 of 1 investors.

AB2 Bio Executive Team (3)

Name Title Board
Seat
Contact
Info
Andrew Sleight Ph.D Chief Executive Officer
Fernando Cunha Chief Financial Officer
Barthélemy Helg Co-Founder & Board Member

You’re viewing 3 of 3 executives.

AB2 Bio Board Members (5)

Name Representing Role Since Contact
Info
Andrea Pfeifer Ph.D Self Chairwoman 000 0000
Barthélemy Helg AB2 Bio Co-Founder & Board Member 000 0000
Bénédict Hentsch AB2 Bio Board Member 000 0000
Erich Hunziker Ph.D Self Board Member 000 0000
Gerald Cagle Ph.D AB2 Bio Board Member 000 0000

You’re viewing 5 of 5 board members.